Glaukos Corporation (GKOS)
NYSE: GKOS · Surgical & Medical Instruments & Apparatus · Aliso Viejo, CA
Our rating: Positive
Call changed from Neutral to Positive at $242.48, moderate conviction, October 29, 2026.
Breaks if: Revenue growth decelerates to below 15% YoY in either of the next two quarterly prints, or trailing-twelve-month free cash flow worsens past -$75M by the end of calendar 2027 — either condition would signal that the operating-leverage story is not developing as the valuation prices in, and would warrant revisiting the call toward Neutral.
Key figures
| Market value | $14.0B |
|---|---|
| Revenue, last 12 months | $690M |
| Net income, last 12 months | −$170M |
| Free cash flow, last 12 months | $36M |
| Price to earnings | n/a |
| Free cash flow yield | 0.3% |
| Dividend yield | 0.0% |
| Operating margin | −25.5% |
| Return on equity | −22.8% |
| Beta to the S&P 500 | 1.23 |
| Volatility, annualized | 53.3% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $211M | 58.0% | $0.03 | $36M |
| June 30, 2026 | $186M | 49.5% | $-0.31 | $12M |
| March 31, 2026 | $151M | 41.2% | $-0.34 | −$16M |
| December 31, 2025 | $143M | 35.7% | $-2.33 | $4M |
| September 30, 2025 | $134M | 38.1% | $-0.28 | −$12M |
| June 30, 2025 | $124M | 29.7% | $-0.34 | $6M |
| March 31, 2025 | $107M | 24.6% | $-0.32 | −$20M |
| December 31, 2024 | $105M | 28.1% | $-0.59 | −$1M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.21B: Claude 92%, Gemini 90%, Mistral 85%
- Diluted earnings per share are above zero: Claude 35%, Gemini 70%, Mistral 62%
- Free cash flow for the quarter is at least $0.00B: Claude 62%, Gemini 85%, Mistral 68%
15 ledger entries and 23 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.